{"id":"NCT00354341","sponsor":"Hoffmann-La Roche","briefTitle":"(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy","officialTitle":"An Open, Randomized, Multi-centre Trial to Investigate the Effect of Anemia Correction on Cardiac Structure and Function in Patients With Early Diabetic Nephropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-09","primaryCompletion":"2005-07","completion":"2005-07","firstPosted":"2006-07-20","resultsPosted":"2016-03-31","lastUpdate":"2016-03-31"},"enrollment":170,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Epoetin beta","otherNames":["NeoRecormon"]}],"arms":[{"label":"Group 1 (Early Epoetin Beta)","type":"EXPERIMENTAL"},{"label":"Group 2 (No/Late Epoetin Beta)","type":"ACTIVE_COMPARATOR"}],"summary":"This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15","timeFrame":"Baseline, Month 15","effectByArm":[{"arm":"Group 1 (Early Epoetin Beta)","deltaMin":0.69,"sd":26.34},{"arm":"Group 2 (No/Late Epoetin Beta)","deltaMin":0.1,"sd":24.25}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8811"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":63,"countries":["Austria","Brazil","Czechia","Denmark","Finland","Germany","Greece","Hungary","Italy","Mexico","Poland","Russia","Singapore","Spain","Sweden","Thailand","United Kingdom"]},"refs":{"pmids":["36791280","17261422"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":88},"commonTop":["Hypertension","Edema peripheral","Renal impairment","Nasopharyngitis"]}}